1

Prospectus Supplement No. 13                    Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 3, 2000)             Registration No. 333-33252



                           HUMAN GENOME SCIENCES, INC.

                              --------------------

                                  $225,000,000
                   5% Convertible Subordinated Notes Due 2007
                                       and
                        4,000,000 Shares of Common Stock
                      Issuable Upon Conversion of the Notes

                              --------------------


                The following information supplements information contained in
        our prospectus dated April 3, 2000, relating to the potential offer and
        sale from time to time by holders of the notes and the underlying shares
        of our common stock. See "Plan of Distribution" in our prospectus.

                This prospectus supplement may only be delivered or used in
        connection with our prospectus. This prospectus supplement is
        incorporated by reference into our prospectus. Our common stock is
        listed on The Nasdaq National Market under the symbol "HGSI."

                NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED
        OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
        SUPPLEMENT OR THE PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION
        TO THE CONTRARY IS A CRIMINAL OFFENSE.




                   Prospectus Supplement dated August 22, 2001

   2


        The notes were originally issued by us and sold by Credit Suisse First
Boston Corporation, as initial purchaser, in a transaction exempt from the
registration requirements of the Securities Act to persons reasonably believed
by the initial purchaser to be qualified institutional buyers or other
institutional accredited investors. Selling holders, including their
transferees, pledgees or donees or their successors, may from time to time offer
and sell any or all of the notes and common stock into which the notes are
convertible.

                              --------------------

        The following table supplements the information in our prospectus with
respect to the selling holders and the principal amounts of notes and common
stock they beneficially own that may be offered under our prospectus. The
information is based on information provided by or on behalf of the selling
holders. All information provided in this prospectus supplement is as of August
13, 2001, and has been adjusted to reflect a two-for-one stock split paid in the
form of a stock dividend on October 5, 2000.

        The selling holders may offer all, some or none of the notes or common
stock into which the notes are convertible. Thus, we cannot estimate the amount
of the notes or the common stock that will be held by the selling holders upon
termination of any sales. The column showing ownership after completion of the
offering assumes that the selling holders will sell all of the securities
offered by this prospectus supplement. In addition, the selling holders
identified below may have sold, transferred or otherwise disposed of all or a
portion of their notes since the date on which they provided the information
about their notes in transactions exempt from the registration requirements of
the Securities Act. None of the selling holders named in the table below has had
any material relationship with us or our affiliates within the past three years.
No selling holder named in the table below beneficially owns one percent or more
of our common stock. Common stock owned prior to the offering and after
completion of the offering includes shares of common stock issuable upon
conversion of our 5 1/2% Convertible Subordinated Notes Due 2006 and 3 3/4%
Convertible Subordinated Notes Due 2007.



                                                                                                                 COMMON
                                                                                                               STOCK OWNED
                                                PRINCIPAL AMOUNT OF        COMMON STOCK        COMMON             AFTER
                                                NOTES BENEFICIALLY        OWNED PRIOR TO        STOCK         COMPLETION OF
NAME                                             OWNED AND OFFERED         THE OFFERING        OFFERED        THE OFFERING
- ----                                             -----------------         ------------        -------        ------------
                                                                                                  
GLG Market Neutral Fund ................            $13,000,000               231,111          231,111              --


        Information concerning the selling holders may change from time to time
and any changed information will be set forth in future prospectus supplements
if and when necessary. Further, the per share conversion price, and therefore
the number of shares of common stock issuable upon conversion of the notes, is
subject to adjustment. As a result, the number of shares of common stock into
which the notes are convertible may increase or decrease.


                                      S-2